Recent Price Movement and Market Context
On 20 Mar 2026, Vivimed Labs Ltd’s stock price fell by 4.09% in a single session, closing at Rs.6.1, its lowest level in the past year. This decline extended a two-day losing streak during which the stock has dropped approximately 7.58%. The stock’s performance notably lagged behind its sector, underperforming by 4.8% on the day. Furthermore, the share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the broader market showed resilience on the same day, with the Sensex rising by 443.30 points or 1.07% to close at 75,002.68. Despite this positive market environment, Vivimed Labs Ltd’s shares continued to weaken, highlighting company-specific pressures. The Sensex itself remains 4.77% above its own 52-week low of 71,425.01, indicating that the stock’s decline is not reflective of general market trends.
Financial Performance and Fundamental Concerns
Vivimed Labs Ltd’s financial indicators reveal several areas of concern that have contributed to the stock’s diminished valuation. The company’s debt-equity ratio stands at a high 9.51 times, indicating a significant leverage burden. This elevated debt level is compounded by a Debt to EBITDA ratio of 12.57 times, suggesting limited capacity to service debt from operational earnings.
Profitability metrics further underscore challenges. The average Return on Equity (ROE) is a modest 1.75%, reflecting low returns generated on shareholders’ funds. Additionally, the company reported a negative EBITDA, which raises questions about its earnings quality and cash flow generation. Over the past year, Vivimed Labs Ltd’s profits have contracted sharply by 386%, despite the stock’s price remaining flat with a 0.00% return over the same period.
The company’s December 2025 results were largely flat, offering little indication of improvement in its financial trajectory. These factors collectively contribute to the stock’s classification as a “Strong Sell” by MarketsMOJO, with a Mojo Score of 17.0. This rating was upgraded from a previous “Sell” grade on 5 Feb 2026, reflecting a deterioration in the company’s fundamental strength.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Valuation and Risk Profile
The stock’s valuation is considered risky relative to its historical averages. Despite the flat price performance over the last year, the underlying profitability has deteriorated significantly, which has weighed on investor sentiment. The company’s micro-cap status further accentuates the volatility and risk associated with its shares.
Technical indicators provide a mixed but predominantly cautious outlook. Weekly and monthly MACD readings are bearish and mildly bullish respectively, while the Relative Strength Index (RSI) remains bearish on both weekly and monthly timeframes. Bollinger Bands also signal bearish trends, and the Dow Theory assessments are mildly bearish across weekly and monthly periods. Daily moving averages show a mildly bullish stance, but this is insufficient to offset the broader negative technical signals.
Shareholding Pattern and Market Position
Vivimed Labs Ltd’s majority shareholders are non-institutional, which may influence liquidity and trading dynamics. The company’s 52-week high was Rs.23.94, indicating a substantial decline of nearly 75% from its peak price. This steep fall highlights the extent of the stock’s downward adjustment over the past year.
Holding Vivimed Labs Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Metrics
To summarise, Vivimed Labs Ltd’s stock has reached a new 52-week low of Rs.6.1, reflecting ongoing financial strain and subdued market confidence. The company’s high leverage, negative EBITDA, and low profitability ratios have contributed to its “Strong Sell” Mojo Grade. Despite a rising Sensex and positive market momentum, the stock’s performance remains weak, trading below all major moving averages and exhibiting bearish technical signals.
Investors monitoring the stock should note the significant gap between the current price and the 52-week high of Rs.23.94, as well as the deteriorated profit metrics over the past year. The micro-cap classification and majority non-institutional shareholding add layers of complexity to the stock’s risk profile.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
